Hugh Sampson - DBV Technologies Chief Scientific Officer
| DBV Stock | EUR 1.25 0.02 1.57% |
Executive
Mr. Hugh A. Sampson, M.D., is an Chief Scientific Officer of the Company. effective on November 1, 2015. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of foodinduced anaphylaxis, the characterization of foodinduced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies for treating food allergies. His research was funded by a number of grants from the National Institutes of Health and private foundations. He is the Principal Investigator of the NIHsponsored Consortium of Food Allergy Research . He is also former President of the American Academy of Allergy Asthma and Immunology . since 2015.
| Age | 70 |
| Tenure | 9 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Philippe Duchateau | Cellectis | 60 | |
| JeanYves Blay | Innate Pharma | 55 | |
| Philippe Moons | Genfit | N/A | |
| Eric Vivier | Innate Pharma | N/A | |
| Florence Sejourne | Genfit | N/A | |
| JeanCharles Soria | Innate Pharma | N/A | |
| Patrick Langlois | Innate Pharma | 70 | |
| MarieBleuenn Terrier | Cellectis | 41 | |
| Frederic Desdouits | Genfit | N/A | |
| Marcus Schindler | Innate Pharma | 51 | |
| Stephan Reynier | Cellectis | N/A | |
| Veronique Chabernaud | Innate Pharma | 56 | |
| Michael Caligiuri | Innate Pharma | 57 | |
| Philippe Pouletty | Innate Pharma | 55 | |
| Karsten Knudsen | Innate Pharma | 44 | |
| Mailys Ferrere | Innate Pharma | 55 | |
| Pierre Dodion | Innate Pharma | 61 | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Ehouarn, Industrial Development and Production Director | ||
| Claude Thebault, Medical Director | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Laurent Martin, Sr. Executive VP of Regulatory and Product Strategy | ||
| Viviane Monges, Non-Executive Independent Director | ||
| Caroline Daniere, Chief Human Resource Officer | ||
| Claire Giraut, Non-Executive Independent Director | ||
| Didier Hoch, Director | ||
| Adam Slatter, Chief Quality Officer | ||
| Daniel Tass, CEO Director | ||
| Daniel Soland, Non-Executive Independent Director | ||
| Julie ONeill, Non-Executive Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Technical Operations Officer | ||
| Charles Ruban, Chief Development Officer | ||
| Nathalie Donne, Director of Bus. Devel. and Corporate Communication | ||
| Ramzi Benamar, Chief Financial Officer | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Chahra Louafi, Director - Representative of CDC Entreprises (Innobio) | ||
| Peter Hutt, Independent Director | ||
| Michele Robertson, Chief Legal Officer | ||
| Rafaele Tordjman, Director - Representative of Sofinnova Partners | ||
| Bertrand Dupont, Co-Founder and Sr. Executive VP of Technology | ||
| MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Veronique Foutel, Chief Strategic Marketing Officer | ||
| Daniel Tasse, Chief Executive Officer, Director | ||
| Rafale Tordjman, Director - Representative of Sofinnova Partners | ||
| Joan Schmidt, Executive Vice President General Counsel | ||
| George Horner, Director | ||
| Michael Goller, Non-Executive Director | ||
| Sebastien Robitaille, Chief Financial Officer | ||
| Torbjorn Bjerke, Non-Executive Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| PierreHenri Benhamou, Chairman of the Board, CEO | ||
| Torbjrn Bjerke, Independent Director | ||
| Kevin Trapp, Chief Commercial Officer | ||
| Mailys Ferrere, Non-Executive Director | ||
| Michel Rosen, Non-Executive Independent Chairman of the Board | ||
| David Schilansky, COO |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | 7.49 X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 28.00 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DBV Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DBV Technologies' short interest history, or implied volatility extrapolated from DBV Technologies options trading.
Pair Trading with DBV Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DBV Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against DBV Stock
| 0.88 | RMS | Hermes International SCA Earnings Call This Week | PairCorr |
| 0.84 | CS | AXA SA | PairCorr |
| 0.79 | CATR | Caterpillar Earnings Call This Week | PairCorr |
| 0.63 | MC | LVMH Mot Hennessy | PairCorr |
| 0.63 | TTE | TotalEnergies SE Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to DBV Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DBV Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DBV Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DBV Technologies SA to buy it.
The correlation of DBV Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DBV Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DBV Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DBV Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade DBV Stock refer to our How to Trade DBV Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |